Orna will receive a $65m upfront payment and is eligible to receive potential milestone payments and royalties.

The deal is set to help Vertex’s development of next-generation gene editing therapies for sickle cell disease and beta-thalassemia.

Orna Therapeutics is dedicated to designing and delivering a new class of fully engineered circular RNA (oRNA ®) therapeutics to unlock the potential of RNA medicine to treat diseases anywhere in ...

WATERTOWN, Mass., Jan. 9, 2025 /PRNewswire/ -- Orna Therapeutics, a biotechnology company dedicated to designing and delivering a new class of circular RNA medicines and unprecedented lipid ...

Orna Therapeutics and Vertex will use lipid nanoparticle system to develop gene-editing therapies for people with SCD and TDT ...

Orna Therapeutics and Shanghai Simnova expand their collaboration to develop RNA-based therapies targeting BCMA for multiple ...

Vertex Pharmaceuticals and Orna Therapeutics announce a $4 billion collaboration to develop in vivo gene editing therapies for sickle cell disease and beta-thalassemia. The partnership leverages ...

Brian currently serves as Chief Business Officer of MPM BioImpact portfolio company Orna Therapeutics. "We are delighted to welcome Brian, a tenured biotechnology executive and expert in strategic ...

Most recently, she served as CFO of Orna Therapeutics, overseeing the company’s finance, investor relations, communications, IT, people and culture, and facilities and lab operations functions. Prior ...